论文部分内容阅读
在重组人红细胞生成素(r-HuEPO)的第二阶段临床试用中,为检验其对血透病人贫血的治疗作用,对5例贫血的血透患者在应用r-HuEPO前后红细胞内酶活性水平进行测定。患者年龄18至70岁,均因慢性肾衰行2-3次/周的维持血透,红细胞压积均低于25%,无其它起严重贫血的疾患。方法: 前四周内每次透析结束时静脉应用1500u-HuEPO,随后六周增至每次3000μ或6000μ,分别于用药前和治疗后红细胞压积增加8%时采血15ml,标本放人肝素抗凝试管内,并即刻存入液氮中,应用国
In the second phase clinical trial of recombinant human erythropoietin (r-HuEPO), in order to test its therapeutic effect on anemia of hemodialysis patients, the level of erythrocyte endogenous enzyme activity in 5 hemodialysis patients with anemia before and after application of r-HuEPO Measurement was performed. Patients aged 18 to 70 years, all due to chronic renal failure 2-3 times / week to maintain hemodialysis, hematocrit less than 25%, no other diseases that cause severe anemia. METHODS: 1500u-HuEPO was intravenously administered at the end of each dialysis at the end of the first four weeks and then increased to 3000μ or 6000μ in each of the six weeks. 15ml of blood was collected before and after treatment with hematocrit of 8% Test tube, and immediately stored in liquid nitrogen, the application of the country